Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 5, 2026, 7:19 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 259 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: dasatinib (SPRYCEL) Clear all
Completed Phase 2 Interventional Results available

Study of Dasatinib (BMS-354825) in Patients With Accelerated Phase Chronic Myeloid Leukemia

NCT00101647
View directory record Official record
Conditions
Chronic Myelogenous Leukemia
Interventions
Dasatinib
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
21
States / cities
Birmingham, Alabama • Anaheim, California • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2011 · Synced Oct 5, 2026, 7:19 AM EDT
Completed Phase 2 Interventional Results available

Open-Label Study Evaluating Dasatinib Therapy Discontinuation in Patients With Chronic Phase Chronic Myeloid Leukemia With Stable Complete Molecular Response

NCT01850004
View directory record Official record
Conditions
Chronic Phase Chronic Myeloid Leukemia
Interventions
Dasatinib
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
8
States / cities
Duarte, California • Los Angeles, California • San Franisco, California + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2022 · Synced Oct 5, 2026, 7:19 AM EDT
Terminated No phase listed Observational

Discontinuation of Imatinib Mesylate in Patients With Chronic-Phase Chronic Myeloid Leukemia Previously Treated With Interferon-Alpha

NCT01073436
View directory record Official record
Conditions
Chronic Myeloid Leukemia
Interventions
Discontinuation of therapy
Other
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 15, 2016 · Synced Oct 5, 2026, 7:19 AM EDT
Terminated Phase 1 Interventional

Treatment With Combination Chemotherapy for Relapsed or Refractory Acute Lymphoblastic Leukemia

NCT03515200
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia With Failed Remission
Interventions
Palbociclib Oral Capsule, Intrathecal Triple Therapy, Dexamethasone, Bortezomib, Dasatinib, Doxorubicin, Ruxolitinib
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 21 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 1, 2020 · Synced Oct 5, 2026, 7:19 AM EDT
Completed Phase 1 Interventional

An Umbrella, Modular Study Based on Epidermal Growth Factor Receptor (EGFR) Mutation Status

NCT00903734
View directory record Official record
Conditions
Advanced Cancers
Interventions
Erlotinib Hydrochloride (Tarceva)
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 13, 2015 · Synced Oct 5, 2026, 7:19 AM EDT
Completed Phase 1 Interventional

Dasatinib in Combination With Bevacizumab to Treat Advanced Solid Tumors

NCT01445509
View directory record Official record
Conditions
Solid Tumors
Interventions
Bevacizumab, Dasatinib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 5, 2026, 7:19 AM EDT
Completed Phase 2 Interventional Results available

Trial of Dasatinib (Sprycel®) in Subjects With Hormone-refractory Prostate Cancer

NCT00570700
View directory record Official record
Conditions
Hormone-refractory Prostate Cancer, Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer, Prostate Cancer, Recurrent Prostate Cancer
Interventions
Dasatinib
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older · Male only
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
6
States / cities
Duarte, California • Loma Linda, California • Orange, California + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2019 · Synced Oct 5, 2026, 7:19 AM EDT
Completed Not applicable Interventional Results available

Study of Oral Dasatinib in Subjects With Myelodysplastic Syndrome (MDS) and Excess Marrow Blasts

NCT00624585
View directory record Official record
Conditions
Myelodysplastic Syndromes
Interventions
Dasatinib
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Dec 16, 2013 · Synced Oct 5, 2026, 7:19 AM EDT
Terminated Phase 2 Interventional Results available

Genomic Guided Therapy With Dasatinib or Nilutamide in Metastatic Castration-Resistant Prostate Cancer

NCT00918385
View directory record Official record
Conditions
Prostate Cancer
Interventions
Nilutamide, Dasatinib
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Male only
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
3
States / cities
Durham, North Carolina • Portland, Oregon • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 29, 2014 · Synced Oct 5, 2026, 7:19 AM EDT
Terminated Phase 1 Interventional

Study of Dasatinib in Patients With Advanced Solid Tumors

NCT00162214
View directory record Official record
Conditions
Tumors
Interventions
Dasatinib + Ketoconazole
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
4
States / cities
Santa Monica, California • Tampa, Florida • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2011 · Synced Oct 5, 2026, 7:19 AM EDT
Terminated Phase 2 Interventional Results available

Dasatinib in Advanced Non-small Cell Lung Cancer (NSCL) With Ex Vivo and In Vivo Assessment of Tumor Target Modulation

NCT00858403
View directory record Official record
Conditions
Lung Cancer
Interventions
Dasatinib
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jan 15, 2014 · Synced Oct 5, 2026, 7:19 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of Dasatinib and Docetaxel in Metastatic Hormone Refractory Prostate Cancer

NCT00439270
View directory record Official record
Conditions
Metastatic Prostate Cancer
Interventions
Dasatinib, Docetaxel
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older · Male only
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
5
States / cities
Chicago, Illinois • Springfield, Illinois • Nyack, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2014 · Synced Oct 5, 2026, 7:19 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Dasatinib in Relapsed or Refractory Non-Hodgkin's Lymphoma

NCT00550615
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma
Interventions
Dasatinib, Dasatinib Maximum Tolerated Dose
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 26, 2023 · Synced Oct 5, 2026, 7:19 AM EDT
Completed Phase 2 Interventional Results available

Dasatinib in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma

NCT00423735
View directory record Official record
Conditions
Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Neoplasm
Interventions
Dasatinib, Pharmacological Study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2018
U.S. locations
184
States / cities
Mobile, Alabama • Scottsdale, Arizona • Tucson, Arizona + 144 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2019 · Synced Oct 5, 2026, 7:19 AM EDT
Withdrawn Phase 2 Interventional

Dasatinib for the Treatment of Moderate and Severe COVID-19

NCT04830735
View directory record Official record
Conditions
Symptomatic COVID-19 Infection Laboratory-Confirmed
Interventions
Dasatinib Anhydrous, Placebo Administration
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 10, 2022 · Synced Oct 5, 2026, 7:19 AM EDT
Completed Phase 2 Interventional Results available

S0622, Dasatinib in Treating Patients With Stage IV Breast Cancer That Has Spread to the Bone

NCT00410813
View directory record Official record
Conditions
Breast Cancer, Metastatic Cancer
Interventions
dasatinib
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
117
States / cities
Mobile, Alabama • Anchorage, Alaska • Bentonville, Arkansas + 76 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 5, 2026, 7:19 AM EDT
Completed Phase 1 Interventional

Hematopoietic Stem Cell Transplant Survivors Study

NCT02652052
View directory record Official record
Conditions
Stem Cell Transplant
Interventions
Standard of Care - Observation Only, Group 2: Quercetin, Group 2: Dasatinib
Other · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 15, 2025 · Synced Oct 5, 2026, 7:19 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Dasatinib or Placebo, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

NCT00869401
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
dasatinib, temozolomide, placebo, radiation therapy
Drug · Other · Radiation
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2019
U.S. locations
207
States / cities
Hartford, Connecticut • Jacksonville, Florida • Columbus, Georgia + 135 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2020 · Synced Oct 5, 2026, 7:19 AM EDT
Completed Phase 2 Interventional Results available

Phase II Dasatinib Study in Advanced Breast Cancer

NCT00546104
View directory record Official record
Conditions
Advanced Breast Cancer
Interventions
Dasatinib
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Female only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
3
States / cities
West Palm Beach, Florida • Charlotte, North Carolina • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 17, 2013 · Synced Oct 5, 2026, 7:19 AM EDT
Completed Phase 2 Interventional Results available

Dasatinib (BMS-354835) Versus Imatinib Mesylate in Subjects With Chronic Myeloid Leukemia

NCT00103844
View directory record Official record
Conditions
Chronic Myeloid Leukemia, Philadelphia-Positive Myeloid Leukemia
Interventions
Dasatinib, Imatinib
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
53
States / cities
Birmingham, Alabama • Anaheim, California • Bakersfield, California + 50 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2010 · Synced Oct 5, 2026, 7:19 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Trial of Dasatinib Plus Ixabepilone in 2nd or 3rd Line Metastatic Breast Cancer

NCT00924352
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Dasatinib, Ixabepilone
Drug
Lead sponsor
Accelerated Community Oncology Research Network
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
13
States / cities
Stamford, Connecticut • Macon, Georgia • Marietta, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2014 · Synced Oct 5, 2026, 7:19 AM EDT
Completed Phase 2 Interventional Results available

Pediatric Philadelphia Positive Acute Lymphoblastic Leukemia

NCT01460160
View directory record Official record
Conditions
Leukemia, Pediatric
Interventions
Dasatinib
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
1 Year to 17 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
88
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 77 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2021 · Synced Oct 5, 2026, 7:19 AM EDT
Active, not recruiting Phase 2 Interventional

Safety And Efficacy Of TKI Cessation For CML Patients With Stable Molecular Response In A Real World Population

NCT04626024
View directory record Official record
Conditions
Chronic Myeloid Leukemia, Chronic Myeloid Leukemia, BCR/ABL-Positive, in Remission, Chronic Myeloid Leukemia in Remission
Interventions
Imatinib Mesylate, Dasatinib, Nilotinib or Bosutinib Withdrawal, Imatinib Mesylate, Dasatinib, Nilotinib or Bosutinib Re-initiation
Other · Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
4
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Oct 5, 2026, 7:19 AM EDT
Completed Phase 1 Interventional

Induction Therapy With Cytarabine, High-Dose Mitoxantrone and Dasatinib for Patients With Philadelphia-Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia

NCT00940524
View directory record Official record
Conditions
Leukemia, Acute Lymphoblastic Leukemia
Interventions
Dasatinib, Mitoxantrone, Cytarabine
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 10, 2014 · Synced Oct 5, 2026, 7:19 AM EDT